FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
17/01/2025
Voltar para busca
Dado oficial do USPTO
CELLUSION
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
27
Atualização mais recente
17/01/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 44
Data de depósito
03/08/2022
Data de registro
09/04/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
09/04/2024
Última transação
17/01/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
JP
Examinador
BLOHM, LINDA
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Cellusion Inc.
Representantes
Holly M. Ford Lewis Oliff PLC
Classificação técnica
Classes Nice
Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Testinginspection and research of pharmaceuticals and consultancy relating thereto; research and development of pharmaceuticals and medical supplies; clinical trials; medical research; biological research; providing information relating to research of medicine; providing information relating to testinginspection or research of medical services using of stem cells; providing information relating to research and development of pharmaceutical preparations; pharmaceutical drug development services; culturing of cells for scientific research purposes; testinginspection or research of medical treatment methods and techniques; testinginspection or research of cosmetics or foodstuffs; scientific research in the field of genetic engineering; scientific services relating to the isolation and cultivation of human tissues and cells; stem cell research services; research and development services in the field of gene expression systems; testinginspection or research of regenerative medicine services; testinginspection or research in the field of cells; culturing of cells for others for scientific research purposes; genetic testing of cells for research purposes; culturing cells for transplantation collected from patients themselves; providing quality assurance services in the field of therapeutic compositionscompositions containing cells for regenerative medicine servicesgene therapyviruses; quality assurance consultancy services in the field of therapeutic compositionscompositions containing cells for regenerative medicine servicesgene therapyviruses; quality control of goods and services of others; consultancy services relating to quality control of goods and services of others
Classe 44
Providing medical information; medical and veterinary information services provided via the Internet; providing information to patients in the field of administering medication; medical care and analysis services relating to patient treatment; health clinic services; collectionanalysisprovision of information relating to medical care; treatment or diagnosis using regenerative medicine services; treatment or diagnosis using cell medicine services; dietary and nutritional guidance; animal breeding; veterinary services; rental of medical apparatus and instruments; providing medical or pharmaceutical consultancy and information services relating to biopharmaceutical products; cultured cell bank services for medical transplantation; medical treatment using cultured cells; stem cell bank services; stem cell therapy services; providing medical information in the field of cells; providing medical information in the field of regenerative medicine services; collection and preservation of biological tissuesblood and cells; treatment and diagnosis performed by culturing medical or clinical cells; medical services; providing information and data for diagnosis and medical treatment; medical treatment with cell preparations; medical professional consulting services; preservation of human blood for use as a source of stem cells; genetic testing for medical purposes; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; health center services
Publicações
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
31/12/2024
FIMP
FINAL DISPOSITION PROCESSED
31/12/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
19/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
09/04/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
09/04/2024
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
09/03/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
23/01/2024
PUBO
PUBLISHED FOR OPPOSITION
23/01/2024
GPNX
NOTIFICATION PROCESSED BY IB
22/01/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
03/01/2024
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
03/01/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
03/01/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/12/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
13/12/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
13/12/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
13/12/2023
RFNP
REFUSAL PROCESSED BY IB
26/07/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/07/2023
RFRR
REFUSAL PROCESSED BY MPU
05/07/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
23/05/2023
CNRT
NON-FINAL ACTION WRITTEN
22/05/2023
DOCK
ASSIGNED TO EXAMINER
22/05/2023
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
10/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
07/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/01/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CELLUSION ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.